Research Advances in the Application of Aptamers for Hematologic Malignancies
ChemBioChem · 13.03.2026 · 27 (5)
DOI: 10.1002/cbic.202500924 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemBioChem, online erschienen am 28.02.2026. Verfasst von Mingyan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Hematologic Neoplasms. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation of China, National Health Commission Science Research Fund-Zhejiang Provincial Health Key Science and Technology Plan Project, Henan Provincial Key Research Project on Science and Technology.
Abstract (Originalsprache)
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma (MM), often present with nonspecific early symptoms that lead to misdiagnosis and delays in initiating treatment. These diseases pose substantial challenges to targeted therapy and prognostic monitoring. Compared with conventional antibodies and small‐molecule inhibitors, aptamers offer several distinct advantages, including high binding affinity, low immunogenicity, and facile chemical modification. These properties make aptamers particularly well‐suited to the clinical needs of hematologic oncology and highlight their promise for improving diagnosis and precision therapeutics. Since the first selection of aptamers targeting malignant hematologic cells two decades ago, the field has achieved remarkable progress. Aptamers have demonstrated considerable potential across key stages of cancer management, from biomarker discovery and tumor detection to targeted therapeutic intervention. This review presents a comprehensive overview of recent advances and provides an in‐depth discussion of future directions and remaining challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
- Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
- Institute of Resources and Environment, Henan Polytechnic University, Jiaozuo, China.
- School of Molecular Medicine, Hangzhou Institute for Advanced Study, UCAS, Hangzhou, China.
- University of Chinese Academy of Sciences, Beijing, China.
ORCID-Profile: Yunfen Hua, Tao Bing
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- National Health Commission Science Research Fund-Zhejiang Provincial Health Key Science and Technology Plan Project
- Henan Provincial Key Research Project on Science and Technology
- University-enterprise collaborative project
Zitieren
APA
Wu, M., Zhang, X., Zhang, M., Chang, T., Hua, Y., & Bing, T. (2026). Research Advances in the Application of Aptamers for Hematologic Malignancies. ChemBioChem, 27(5). https://doi.org/10.1002/cbic.202500924
Vancouver
Wu M, Zhang X, Zhang M, Chang T, Hua Y, Bing T. Research Advances in the Application of Aptamers for Hematologic Malignancies. ChemBioChem. 2026;27(5). doi:10.1002/cbic.202500924
BibTeX
@article{Wu2026,
author = {Wu, Mingyan and Zhang, Xiangru and Zhang, Mingxin and Chang, Tianjun and Hua, Yunfen and Bing, Tao},
title = {Research Advances in the Application of Aptamers for Hematologic Malignancies},
journal = {ChemBioChem},
year = {2026},
volume = {27},
number = {5},
doi = {10.1002/cbic.202500924}
}
EUVIMED